-
Dr. Raksha Kochi: Interpreting Gram Stain Results with ChatGPT | ESCMID Global 2024
Editor’s Note: Traditional microbiology laboratory methods such as Gram staining and antimicrobial susceptibility testing still rely on manual interpretation of results and report generation. The introduction of artificial intelligence (AI)…
-
Professor Tiejun Gong: Striving for Excellence, 2024 CSCO Guidelines on Malignant Hematology with a Focus on Leukemia | 2024 CSCO Guidelines Conference
The 2024 China Clinical Oncology Society (CSCO) Guidelines Conference was held in Jinan on April 26-27, 2024. As always, the conference updated and released multiple CSCO cancer treatment guidelines. Professor Tiejun Gong, Deputy Director of the Harbin Institute of Hematologic Oncology, gave an insightful interpretation of the leukemia section in the “2024 CSCO Guidelines on…
-
EBMT 2024 | Dr. Li Gao：The MRD status on day 7 and CD4 count at 1 month after CAR-T therapy are prognostic indicators in CAR-T treatments
From April 14 to 17, 2024, the 50th Annual Congress of the European Society for Blood and Marrow Transplantation (EBMT) was held with great ceremony in Glasgow, UK. The conference focused on the latest advancements in stem cell transplantation and cell therapy, advancing patients with hematological diseases towards better clinical prognoses. At this congress, Dr.…
-
2024 CUDA Yanqi Lake Conference | Professor Xuesong Li: Optimizing Prostate Cancer Management to Safeguard Men’s Lives
The “4th Chinese Medical Association Urology Surgeons Branch Yanqi Lake Conference (2024)” was successfully held in Beijing from April 13th to 14th. The conference not only focused on clinical practices in urology surgery but also discussed cutting-edge developments and important topics in the industry. At the conference, Professor Xuesong Li from Peking University First Hospital…
-
2024 CSCO Guideline Symposium: Professor Tiejun Gong: “Updates to the CSCO Guidelines for Malignant Hematologic Diseases” Drive Clinical Diagnosis
With the development of targeted therapy and immunotherapy, the treatment options for malignant hematologic diseases continue to expand. The “Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Malignant Hematologic Diseases (2024)” has once again been updated. “Oncology Watch” specially interviewed one of the guideline’s authors, Professor Tiejun Gong from the…
-
Professor Qing Cao’s Commentary: Emerging Staphylococcus Threatens Newborn Health | ESCMID Global 2024
In low- and middle-income countries, the health of newborns faces numerous challenges, with neonatal sepsis being a particularly grave concern. At the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024), a study (abstract number: O0158) focused on the threat posed by Coagulase-Negative Staphylococci (CoNS) to newborn health. These bacteria, increasingly reported…
-
EBMT Distinguished Interview | Optimizing Induction Therapy Before ASCT: From Past to Future
Induction therapies with high remission rates, combined with high-dose chemotherapy and autologous stem cell transplantation (ASCT), have significantly improved the prognosis for multiple myeloma (MM) patients. Despite this, patients still inevitably experience disease progression or relapse. One of the key goals in this research field is how to maintain remission in patients after induction therapy…
-
Professor Wei Yu Shares Research Progress in NMIBC Treatment | EAU24 Expert Commentary
Transurethral resection of bladder tumors (TURBt) is the conventional treatment for non-muscle-invasive bladder cancer (NMIBC). Patients are stratified into low, intermediate, high, and very high risk categories, with different postoperative bladder instillation treatments and follow-up monitoring strategies for different risk patients. Several advancements in NMIBC research were presented at the recent EAU conference, and “Oncology…
Connecting Medical Expertise through Media